Evidence mapPaperPMID 21688044Full record

SynthesisJournal of neurology2012

Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.

Sergi Martinez-Ramirez, Raquel Delgado-Mederos, Rebeca Marín, Marc Suárez-Calvet, María Pilar Sáinz, Aída Alejaldre, Ángela Vidal-Jordana, Josep Lluís Martí-Vilalta, Joan Martí-Fàbregas

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Statin, cholesterol, and sICH after acute ischemic stroke: systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Pooled it
  4. Pooled it
  5. Trial
  6. Observational
  7. Article
  8. Article
  9. Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke.International journal of molecular sciences · 2016
    Review
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sergi Martinez-RamirezNeurology Department, Hospital de la Santa Creu i Sant Pau, 167 Sant Antoni Maria Claret st., 08025 Barcelona, Spain. smartinezr@santpau.cat
Raquel Delgado-Mederos
Rebeca Marín
Marc Suárez-Calvet
María Pilar Sáinz
Aída Alejaldre
Ángela Vidal-Jordana
Josep Lluís Martí-Vilalta
Joan Martí-Fàbregas

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influence of statins on the results of intravenous thrombolysis for ischemic stroke is controversial. We studied the risks and benefits of statin pretreatment (SP) in patients treated with intravenous alteplase (t-PA) at our institution, and included our data to a meta-analysis of previous related studies. We reviewed prospectively collected data from consecutive patients with acute ischemic stroke treated with IV rt-PA at our institution over the past 9 years. We compared symptomatic intracranial haemorrhage (SICH), favourable short-term outcome (decrease of ≥4 points on the NIHSS score after 24 h from baseline assessment), favourable long-term outcome (mRS score ≤2 at 3 months) and mortality rates between statin-pretreated (SPP) and nonstatin-pretreated patients (NSPP). We performed a systematic search through MEDLINE/PubMed and Embase datasets to identify similar English language studies. A total of 182 patients were included (mean age 68.3 ± 11.4 years, 54.3% men). There were no significant differences between SPP and NSPP regarding SICH (3.3 vs. 1.7%, p = 0.47), favourable short-term outcome (44.8 vs 56%, p = 0.31) and favourable long-term outcome rates (40 vs 44.1%, p = 0.84). In a meta-analysis of 1,055 patients, SP was neither related to long-term functional outcome nor mortality, but it was a risk factor for SICH (OR 1.99, 95% CI 1.03-3.84, p = 0.04). Statin pretreatment may increase the risk of SICH in patients receiving IV t-PA for ischemic stroke, though it does not influence the 3 months outcome. Prospective studies are needed to confirm this safety concern.

Indexed as

AgedBrain IschemiaCase-Control StudiesFemaleFibrinolytic AgentsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInjections, IntravenousIntracranial HemorrhagesMaleMiddle AgedPlatelet Aggregation InhibitorsPrognosisProspective StudiesRisk AssessmentRisk FactorsFibrinolytic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsTissue Plasminogen Activator

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.